Skip to main content
. 2021 Nov 29;16(5):804–821. doi: 10.1093/ecco-jcc/jjab216

Table 3.

Correlation between fibrosis burden score and clinical factors

Factor Categories N Statistics p-value
Gender Male 37 0.75 [0.33, 1.00] 0.136
Female 24 1.00 [0.63, 1.33]
Family history
 CD Yes 6 1.00 [0.75, 1.50] 0.654
No 54 1.00 [0.50, 1.33]
 UC Yes 12 1.00 [0.33, 1.00] 0.228
No 48 1.00 [0.67, 1.33]
Smoker Current 1 1.33 [1.33, 1.33] 0.398
Ex-smoker 0 -
Never 57 1.00 [0.50, 1.33]
Extraintestinal manifestations
• Joint Yes 6 0.67 [0.42, 0.92] 0.316
No 55 1.00 [0.50, 1.33]
• Skin Yes 1 3.00 [3.00, 3.00] 0.115
No 60 1.00 [0.50, 1.33]
• Eye Yes 0 - NA
No 61 1.00 [0.50, 1.33]
• Bone Yes 0 - NA
No 61 1.00 [0.50, 1.33]
• Anaemia Yes 26 1.00 [0.69, 1.46] 0.090
No 35 0.75 [0.50, 1.00]
• PSC Yes 1 2.00 [2.00, 2.00] 0.160
No 60 1.00 [0.50, 1.33]
• None Yes 29 0.75 [0.50, 1.00] 0.068
No 32 1.00 [0.67, 1.33]
Backwash ileitis Yes 12 1.00 [0.69, 1.37] 0.634
No 48 1.00 [0.50, 1.33]
Extent of colitis Extensive 58 1.00 [0.50, 1.33] 0.429
Left 3 0.75 [0.54, 0.88]
Proctitis 0 -
Medications prior to colectomy
• Immunomodulators Yes 43 1.00 [0.67, 1.33] 0.822
No 14 1.00 [0.54, 1.33]
• Anti-TNF Yes 37 1.00 [0.75, 1.67] 0.005
No 19 0.67 [0.33, 1.00]
• Vedolizumab Yes 1 0.33 [0.33, 0.33] 0.104
No 22 1.00 [0.69, 1.31]
Medications at time of colectomy
• 5-ASA Yes 12 1.00 [0.67, 1.42] 0.602
No 49 1.00 [0.50, 1.33]
• Systemic steroids Yes 52 1.00 [0.67, 1.33] 0.100
No 9 0.50 [0.33, 0.75]
• 6MP Yes 6 0.83 [0.35, 1.00] 0.261
No 55 1.00 [0.50, 1.33]
• AZA Yes 6 1.00 [0.81, 2.50] 0.226
No 55 1.00 [0.50, 1.33]
• MTX Yes 9 1.00 [1.00, 1.50] 0.166
No 52 1.00 [0.50, 1.33]
• Vedolizumab Yes 0 - NA
No 61 1.00 [0.50, 1.33]
• Anti-TNF Yes 14 1.17 [0.75, 2.00] 0.020
No 47 1.00 [0.50, 1.12]
• Sulphasalazine Yes 1 1.00 [1.00, 1.00] 0.819
No 60 1.00 [0.50, 1.33]
• Cyclosporine Yes 2 0.88 [0.81, 0.94] 0.951
No 59 1.00 [0.50, 1.33]
• Tacrolimus No 60 1.00 [0.50, 1.33] 0.819
Yes 1 1.00 [1.00, 1.00]
Duration of immunomodulators 28 -0.15 [ -0.50, 0.24 ] 0.45
Duration of anti-TNF 28 -0.28 [-0.59, 0.10] 0.15

Values presented as median [25th, 75th percentile] with Kruskal–Wallis test or Spearman’s rho [95% confidence interval].

BMI, body mass index, CD, Crohn’s disease; UC, ulcerative colitis; PSC, primary sclerosing cholangitis; 5- ASA, 5-aminosalicylic acid, 6MP, mercaptopurine; AZA, azathioprine; MTX, methotrexate; TNF, tumour necrosis factor; NA, not available.